Maravai Lifesciences Holdings, Inc. Class A (MRVI)

In the past six months, Maravai Lifesciences Holdings, Inc. reported its third-quarter 2025 financial results on November 6, 2025, followed by its fourth-quarter and full-year 2025 financial results on February 25, 2026. For the full year 2025, Maravai reported a 28.3% decrease in revenue compared to the prior year, primarily due to a lack of high-volume CleanCap orders for commercial phase vaccine programs. The company provided guidance for 2026, anticipating revenue between $200 million and $210 million and adjusted EBITDA between $18 million and $20 million, driven by organizational restructuring and cost-saving initiatives. The company has undergone organizational restructuring and implemented operating cost reduction initiatives, including workforce reductions, to align its cost structure. Leadership transitions have also occurred, including the appointment of a new Chief Executive Officer and Chief Financial Officer. Maravai's stock has seen fluctuations, with a 6-month performance of +30.8% as of April 2026, and a 52-week trading range between $1.67 and $4.11. Analysts have given MRVI a consensus "Hold" rating, with an average one-year target price of $5.38.

Demand for Maravai Lifesciences' products and services can be influenced by factors such as large-volume orders for commercial phase vaccine programs and general spending on discovery products. A lack of high-volume CleanCap orders for commercial phase vaccine programs significantly impacted TriLink's revenue in 2025. While the information suggests demand can fluctuate based on these significant projects and overall research activity, it does not explicitly detail a recurring seasonal pattern.

Maravai Lifesciences Holdings, Inc. is a life sciences company providing critical products for novel vaccines, drug therapies, diagnostics, and research into human diseases. The company operates within the Health Technology sector and the Biotechnology industry, with major brands including TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. Through its TriLink segment, Maravai manufactures and sells products used in gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents for DNA and RNA synthesis, modification, labeling, and purification. Key patented products and services from TriLink include CleanCap® mRNA capping technology and CleanAmp®. The Cygnus segment focuses on biologic safety testing products and specialized analytical products for use in biologic manufacturing process development, offering custom product-specific antibody and assay development services.

Maravai Lifesciences Holdings, Inc. has a global geographic footprint, operating through segments that include North America, Asia Pacific, Europe, the Middle East, Africa, and Latin and Central America. The company's headquarters are located in San Diego, California.

Maravai Lifesciences maintains a reputation as a leading life sciences company providing critical products for drug therapies, vaccines, diagnostics, and research. Its portfolio companies are ISO-9001:2015 certified and have been cited hundreds of thousands of times in peer-reviewed scientific publications, indicating a strong scientific standing. In the past year, the company has announced license and supply agreements for its CleanCap mRNA capping technology, which can positively impact its brand by demonstrating continued innovation and partnerships in the mRNA space. The company's focus on operational excellence and efforts to restore profitability through restructuring initiatives also contribute to its corporate reputation.

Maravai Lifesciences Holdings, Inc. has significant institutional ownership, with 167 institutional owners and shareholders holding a total of 128,161,938 shares as of April 6, 2026. Institutional ownership accounts for approximately 89.61% of shares outstanding, while insider ownership is around 6.7%. Major institutional owners include Gtcr Llc, BlackRock, Inc., 12 West Capital Management LP, Braidwell Lp, Vanguard Group Inc, Mackenzie Financial Corp, Renaissance Technologies Llc, Monaco Asset Management SAM, Morgan Stanley, and Philosophy Capital Management LLC.